Literature DB >> 2936901

The long terminal repeat of the intracisternal A particle as a target for transactivation by oncogene products.

S Luria, M Horowitz.   

Abstract

It has been shown recently that the c-mos oncogene becomes activated in myeloma XRPC-24 via insertion of an intracisternal A particle (IAP) long terminal repeat (LTR). The inserted LTR serves as a promoter from which transcription of the 3' rearranged c-mos initiates. The insertion is in a head-to-head orientation such that the transcriptional orientations of the IAP and the 3' rearranged c-mos are opposite. It has already been shown that this IAP LTR has two promoters, one transcribing the IAP genome and the other transcribing the rearranged c-mos. Since the IAP genomes are actively transcribed in mouse myelomas but not in normal cells, it was interesting to test whether transcriptional activation of the IAP occurs in the presence of active oncogene products, especially nuclear ones. The 5' LTR of the IAP inserted in myeloma XRPC-24 was chosen as a convenient model to test the effect of viral and cellular oncogene products. These included simian virus 40 (SV40) large-T antigen, the adenovirus early 1A (E1A) gene product, the myc gene product, and p53. The LTR was coupled to the bacterial gene coding for chloramphenicol acetyltransferase (CAT) in two orientations, and the levels of CAT directed by the LTR promoters were assayed in either the presence or the absence of the oncogene products. The levels of CAT directed by the 5' LTR promoter transcribing the IAP were significantly elevated in the presence of SV40 large-T antigen, the adenovirus E1A and myc gene products, and p53. The promoter transcribing the rearranged c-mos was transactivated by SV40 large-T antigen and the adenovirus E1A gene product. The results indicate that oncogene products may have an important role in turning on promoters of other genes. The IAP LTR may serve as a useful model for studying the effect of various gene products on promoters which are known to be activated in the malignant state.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2936901      PMCID: PMC252832     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  33 in total

1.  Characteristics of a human cell line transformed by DNA from human adenovirus type 5.

Authors:  F L Graham; J Smiley; W C Russell; R Nairn
Journal:  J Gen Virol       Date:  1977-07       Impact factor: 3.891

2.  An adenovirus type 5 early gene function regulates expression of other early viral genes.

Authors:  N Jones; T Shenk
Journal:  Proc Natl Acad Sci U S A       Date:  1979-08       Impact factor: 11.205

3.  Adenovirus 5 DNA sequences present and RNA sequences transcribed in transformed human embryo kidney cells (HEK-Ad-5 or 293).

Authors:  L Aiello; R Guilfoyle; K Huebner; R Weinmann
Journal:  Virology       Date:  1979-04-30       Impact factor: 3.616

4.  A new technique for the assay of infectivity of human adenovirus 5 DNA.

Authors:  F L Graham; A J van der Eb
Journal:  Virology       Date:  1973-04       Impact factor: 3.616

5.  Overproduction of p53 antigen makes established cells highly tumorigenic.

Authors:  D Eliyahu; D Michalovitz; M Oren
Journal:  Nature       Date:  1985 Jul 11-17       Impact factor: 49.962

6.  RNA sequences specifically associated with mouse intracisternal A particles.

Authors:  K K Lueders; S Segal; E L Kuff
Journal:  Cell       Date:  1977-05       Impact factor: 41.582

7.  SV40-transformed simian cells support the replication of early SV40 mutants.

Authors:  Y Gluzman
Journal:  Cell       Date:  1981-01       Impact factor: 41.582

8.  Mechanism of activation of early viral transcription by the adenovirus E1A gene product.

Authors:  J R Nevins
Journal:  Cell       Date:  1981-10       Impact factor: 41.582

9.  Pre-early adenovirus 5 gene product regulates synthesis of early viral messenger RNAs.

Authors:  A J Berk; F Lee; T Harrison; J Williams; P A Sharp
Journal:  Cell       Date:  1979-08       Impact factor: 41.582

10.  Early mouse embryo intracisternal particle: Fourth type of retrovirus-like particle associated with the mouse.

Authors:  Y Yotsuyanagi; D Szöllösi
Journal:  J Natl Cancer Inst       Date:  1981-09       Impact factor: 13.506

View more
  7 in total

Review 1.  Mechanisms of transcriptional regulation of cellular genes by SV40 large T- and small T-antigens.

Authors:  U Moens; O M Seternes; B Johansen; O P Rekvig
Journal:  Virus Genes       Date:  1997       Impact factor: 2.332

2.  Stage-specific expression of intracisternal A-particle sequences in murine myelomonocytic leukemia cell lines and normal myelomonocytic differentiation.

Authors:  Y Takayama; M A O'Mara; K Spilsbury; R Thwaite; P B Rowe; G Symonds
Journal:  J Virol       Date:  1991-04       Impact factor: 5.103

3.  Intracisternal A-type particle-mediated activations of cytokine genes in a murine myelomonocytic leukemia: generation of functional cytokine mRNAs by retroviral splicing events.

Authors:  K B Leslie; F Lee; J W Schrader
Journal:  Mol Cell Biol       Date:  1991-11       Impact factor: 4.272

4.  The intracisternal A particle derived solo LTR promoter of the rat oncomodulin gene is not present in the mouse gene.

Authors:  D Banville; M Rotaru; Y Boie
Journal:  Genetica       Date:  1992       Impact factor: 1.082

5.  Expression of intracisternal A-type particles is increased when a B-cell lymphoma differentiates into an immunoglobulin-secreting cell.

Authors:  D L Wiest; J K Burkhardt; A M Stockdale; Y Argon
Journal:  J Virol       Date:  1989-02       Impact factor: 5.103

6.  Multiple protein-binding sites in an intracisternal A particle long terminal repeat.

Authors:  M Falzon; E L Kuff
Journal:  J Virol       Date:  1988-11       Impact factor: 6.549

7.  Suppressible and nonsuppressible autocrine mast cell tumors are distinguished by insertion of an endogenous retroviral element (IAP) into the interleukin 3 gene.

Authors:  H H Hirsch; A P Nair; C Moroni
Journal:  J Exp Med       Date:  1993-08-01       Impact factor: 14.307

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.